Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-12-21
2008-10-21
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S102000
Reexamination Certificate
active
07439239
ABSTRACT:
Disclosed are compounds, compositions and methods for treating various diseases and conditions, including pain. Such compounds are represented by Formula I as follows:wherein A, G, Y, R3-R5are defined herein.
REFERENCES:
patent: 2368006 (1945-01-01), Cusic
patent: 2784185 (1957-03-01), Wilhelm
patent: 2901478 (1959-08-01), Wilhelm
patent: 3179665 (1965-04-01), Schmutz
patent: 3305547 (1967-02-01), Stach et al.
patent: 3470188 (1969-09-01), Kaiser et al.
patent: 3557287 (1971-01-01), Berde et al.
patent: 3931232 (1976-01-01), Bender et al.
patent: 3987042 (1976-10-01), Gueremy et al.
patent: 4086350 (1978-04-01), Zirkle
patent: 4275209 (1981-06-01), Lassen et al.
patent: 4356184 (1982-10-01), Deason et al.
patent: 4666907 (1987-05-01), Fortin et al.
patent: 4777177 (1988-10-01), Traber et al.
patent: 5502049 (1996-03-01), Garret et al.
patent: 6004983 (1999-12-01), Andersen et al.
patent: 6114354 (2000-09-01), Andersen et al.
patent: 6153626 (2000-11-01), Pelcman et al.
patent: 7060711 (2006-06-01), Lubbert et al.
patent: 2003/0018447 (2003-01-01), Florschuetz
patent: 2003/0166672 (2003-09-01), Lubbert et al.
patent: 2005/0009860 (2005-01-01), Carson et al.
patent: 2006/0030585 (2006-02-01), Dax et al.
patent: 2006/0135522 (2006-06-01), Carson et al.
patent: 2006/0135524 (2006-06-01), Carson et al.
patent: 2006/0135763 (2006-06-01), Coats et al.
patent: 2006/0148823 (2006-07-01), Coats et al.
patent: 2006/0287297 (2006-12-01), DeCorte et al.
patent: 2009555 (1970-02-01), None
patent: 0005607 (1979-11-01), None
patent: 1306376 (2003-05-01), None
patent: 1321169 (2003-06-01), None
patent: 1049676 (2005-10-01), None
patent: 2290202 (1976-06-01), None
patent: 1128734 (1968-10-01), None
patent: WO 98/28275 (1998-07-01), None
patent: WO 99000376 (1999-01-01), None
patent: WO 01/46191 (2001-06-01), None
patent: WO 01066543 (2001-09-01), None
patent: WO 01/72303 (2001-10-01), None
patent: WO 02/36573 (2002-05-01), None
patent: WO 02/48122 (2002-06-01), None
patent: WO 03035646 (2003-05-01), None
patent: WO 2004/035541 (2004-04-01), None
patent: WO 04026030 (2004-04-01), None
patent: WO 2004/092165 (2004-10-01), None
patent: WO 2005/003131 (2005-01-01), None
Thomas, J.B. et al. “4-[(8-Alkyl-8-azabicyclo[3.2.1])-3-arylanilino]-N,N-diethyl benzami des: High Affinity, Selective Ligands for the Delta Opiod Receptor Illustrate Factors Important to Antagonist Activity”, Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 10, No. 11, Jun. 2000, pp. 1281-1284. XP004200575.
Boyd, R.E. et al. “Synthesis and Binding Affinities of 4-diarylaminotropanes, A New Class of Delta Opioid Agonists”, Bioorganic & Medicinal Chemistry Letters, vol. 10, No. 10, 2000, pp. 1109-1111. XP002383686.
U.S. Appl. No. 11/313,704, filed Dec. 21, 2005, Janssen Pharmaceutica N.V.
U.S. Appl. No. 11/314,300, filed Dec. 21, 2005, Janssen Pharmaceutica N.V.
U.S. Appl. No. 11/326,084, filed Jan. 5, 2006, Janssen Pharmaceutica N.V.
PCT Intl. Search Report, PCT/US2005/046691, Jun. 26, 2006.
Bidlack, J.M. et al.: “8-Carboxamidocyclazocine: A Long-Acting, Novel Benzomorphan”, J. Pharm. & Exp. Ther. 2002, pp. 374-380, vol. 302, No. 1.
Catalog Frontier Scientific, Logan, UT. (online http://www.frontiersci.com/browse.php?browse=Boronic%20acid2007)—in U.S. Appl. No. 11/314,300.
Commercial 2-Bromo-Phenols from Sigma-Aldrich, 2007.
Commercial 4-piperidinones, 2007.
Connor, M. et al.: “Opioid Receptor Signalling Mechanisms”; Clinical and Experimental Pharmacology and Physiology 1999, 26, 493-499.
Dorwald, F.Z.: Side Reactions in Organic Synthesis, 2005, Wiley; VCH, Weinheim p. 1X of Prefac & Chapter 8, 279-308.
Frontier Scientific (Logan, UT) Commercial Boronic Acids—in U.S. Appl. No. 11/313,704, 2007.
Hutchins, R.O. et al.: “Selective Reductive Displacement of Alkyl Halides and Sulfonate Esters with Cyanoborohydride Reagents in Hexamethylphosphoramide”; J. Org. Chem. (1977) 42(1) 82-91.
Kaiser, C. et al., “Analogs of Phenothiazines. 5. Synthesis and Neuropharmacological Activity of Some Piperidylidene Derivatives of Thioxanthenes, Xanthenes, Dibenzoxepins, and Acridans”,J. Med. Chem., 1974, vol. 17, No. 1, pp. 57-62.
Kenakin, T. et al.: “The ligand paradox between affinity and efficacy: can you be there and not make a difference?” TRENDS in Pharmacological Sciences 2002, 23(6), 275-280.
Loughhead, D.G.: “Unusual Reductions Induced by Formic Acid”; Tetrahedron Letters 1988, 29(45) 5701-5702.
Quock et al.: “The d-Opioid Receptor: Molecular Pharmacology, Signal Transduction, and the Determination of Drug Efficacy”; Pharmacological Reviews 1999, 51(3), 503-532.
Sun, X., et al. “Synthesis and Opioid Receptor Binding Properties of Conformation-Rigidified Analogues of 8-Carboxamidocyclazocine and 8-Formamidocyclazocine”, Abstract of Papers, 229thACS Natl. Mtg., N.Y. 2005.
Thomas, J.B. et al.: “(±)-4-[(N-Allyl-CIS-3-Methyl-4-Piperidinyl)Phenylamino]-N,N-Diethylbenzamide Displays Selective Binding for the Delta Opioid Receptor”; Bioorganic & Med. Chem. Letters 1999, 9(20) 3053-3056.
Thomas, J.B. et al.: “Factors Influencing Agonists Potency and Selectivity for the Opioid δ Receptor Are Revealed in Structure—Activity Relationship Studies of the 4-[(N-Substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides”; J. Med. Chem. 2001, 44(6) 972-987.
Val Alstine, M. A.: “Synthesis and evaluation of novel N-substituted derivatives of 8-carboxamidocyclazocine”, Abstract of papers 231stACS National Meeting, Atlanta, GA, 2006, MEDI-009.
Walpole, C.S.J. et al.: “The Discovery of Capsazepine, the First Competitive Antagonist of the Sensory Neuron Excitants Capsaicin and Resiniferatoxin”; J. Med. Chem. 1994, 37, 1942-1954.
Wentland, M. et al., “8-Aminocyclazocine Analogues: Synthesis and Structure-Activity Relationships”, Bioorganic & Med. Chem. Lett., 2000, pp. 183-187, vol. 10, No. 2.
Wentland, M. et al., “Selective Protection and Functionalization of Morphine: Synthesis and Opioid Receptor Binding Properties of 3-Amino-3-desoxymorphine Derivatives”, J. Med. Chem. 2000, pp. 3558-3565, vol. 43, No. 19.
Wentland, M. et al., “3-Carboxamide Analogues of Morphine and Naltrexone: Synthesis and Opioid Receptor Binding Properties”, Bioorganic & Med. Chem. Lett., 2001, pp. 1717-1721, vol. 11.
Wentland, M. et al., “8-Carboxamidocyclazocine Analogues: Redefining the Structure-Activity Relationships of 2,6-Methano-3-benzazocines”, Bioorganic & Med. Chem. Lett., 2001, pp. 623-626, vol. 11.
Wentland, M. et al., “Synthesis and Opioid Receptor Binding Affinities of 8-Amino-2,6-methano-3-benzazocines”, J. Med. Chem. 2003, pp. 838-849, vol. 46.
Wentland, M. et al., “Redefining the Structure—Activity Relationships of 2,6-Methano-3-benzazocines. Part 2: 8-Formamidocylclazocine Analogues”. Bioorganic & Med. Chem. Lett. 2003, pp. 1911-1914, vol. 13.
Wentland, M. et al., “Thioformamido and Thiocarboxamido Derivatives of Cyclazocine: Syntheses and Opioid Receptor Binding Properties”, Abstract of Papers, 226thACS Natl. Mtg., N.Y. 2003.
Wentland, M. et al., “Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone”, Bioorganic & Med. Chem. Lett., 2005, pp. 2107-2110.
Wentland, M. et al.: “Redefining the structure—activity relationships of 2,6-methano-3-benzazocines. Part 3: 8-Thiocarboxamido and 8-thioformamido derivatives of cyclazocine.”; Bioorg. & Med. Chem. Lett. 15 (2005) 2547-2551.
Zhang, A. et. al.: “10-Ketomorphinan and 3-Substituted-3-desoxymorphinan Analogues as Mixed κ and μ Opioid Ligands: Synthesis and Biological Evaluation of Their Binding Affinity at Opioid Receptors”, J. Med. Chem., 2004, pp. 165-174, vol. 47, No. 1.
Zhang, X. et al.: “Probes for Narcotic Receptor Medi
Coats Steve
Dax Scott L.
DeCorte Bart
Liu Li
McDonnell Mark
Habte Kahsay T
Janssen Pharmaceutica N.V.
LandOfFree
Tricyclic δ- opioid modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic δ- opioid modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic δ- opioid modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002211